Basilea Pharmaceutica AG
BPMUF
$77.40
$11.9018.17%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 57.11M | 57.77M | 65.00M | 64.91M | 54.86M |
| Total Other Revenue | 16.50M | 16.70M | 15.38M | 15.36M | 8.16M |
| Total Revenue | 73.61M | 74.46M | 80.37M | 80.27M | 63.01M |
| Cost of Revenue | 42.96M | 43.46M | 51.75M | 51.69M | 37.90M |
| Gross Profit | 30.65M | 31.00M | 28.62M | 28.58M | 25.12M |
| SG&A Expenses | 10.85M | 10.97M | 11.18M | 11.16M | 10.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.81M | 54.43M | 62.93M | 62.85M | 48.23M |
| Operating Income | 19.80M | 20.03M | 17.44M | 17.42M | 14.78M |
| Income Before Tax | 19.89M | 20.12M | 16.60M | 16.58M | 11.73M |
| Income Tax Expenses | 2.60M | 2.63M | 1.31M | 1.31M | 2.15M |
| Earnings from Continuing Operations | 17.29M | 17.49M | 15.29M | 15.27M | 9.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.29M | 17.49M | 15.29M | 15.27M | 9.58M |
| EBIT | 19.80M | 20.03M | 17.44M | 17.42M | 14.78M |
| EBITDA | 19.86M | 20.09M | 18.66M | 18.63M | 15.30M |
| EPS Basic | 1.40 | 1.41 | 1.25 | 1.25 | 0.78 |
| Normalized Basic EPS | 1.01 | 1.02 | 0.85 | 0.85 | 0.62 |
| EPS Diluted | 1.31 | 1.33 | 1.18 | 1.18 | 0.78 |
| Normalized Diluted EPS | 0.91 | 0.92 | 0.77 | 0.77 | 0.60 |
| Average Basic Shares Outstanding | 12.37M | 12.37M | 12.24M | 12.24M | 12.25M |
| Average Diluted Shares Outstanding | 13.81M | 13.81M | 13.52M | 13.52M | 12.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |